louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03738176: The Efficacy of Topical Sesame Oil Versus Topical Triamcinolone on Oral Lichen Planus and Salivary Level of Oxidative Stress Biomarker [MDA]
Official title: The Efficacy of Topical Sesame Oil in Orabase Versus Topical Triamcinolone in Orabase on Oral Lichen Planus and Salivary Level of Oxidative Stress Biomarker, Malondialdehyde [MDA] : Randomized Clinical Trial (RCT)
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: EARLY_PHASE1
Conditions: Oral Lichen Planus
Keywords: Oral lichen planus
sesame oil
corticosteroid
MDA
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2018-11-13
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: sesame oil in orabase(80 gm CMC -20 gm sesame oil)
Primary purpose: TREATMENT

Brief summary: use seseme oil and corticosteroid topically for two groups

Detailed description: * The enrolled patients will be divided randomly into two groups.
* Test group will receive topical sesame oil (3 times /day after eating) for a month.
* Control group will receive topical corticosteroid (3 times /day after eating) for a month.
* Assessment of the appearance score and severity of pain as well as the clinical parameter outcome will be done at baseline and at the end of two and four weeks and will be recorded in the patients' questionnaires \& by clinical sign score . MDA will be measured at the baseline \& at the end of four weeks after treatment.

Eligibility criteria: Inclusion Criteria:

* Patients who will be clinically diagnosed as having atrophic \&/or erosive oral lichen planus.

  * Patients with no history of taking topical corticosteroids for the last 2 months and systemic corticosteroid for the last 6 months
  * Patients who agree to take medication and follow up .

Exclusion Criteria:

* Pregnant and lactating ladies.

  * Patients with history of topical steroids during last 2 months \& systemic steroids during last 6 months.
  * Patients with recent dental filling associated with the lesion or associated with recent drug administration.
  * Patient with history of diabetes or hypertension or those with positive HCV ab or HBs Ag.

Primary outcomes:
measure: pain intensit measure
timeFrame: 4 weeks
measure: reduction of clinical signs measure
timeFrame: 4 weeks
Secondary outcomes:
measure: Salivary level of oxidative stress biomarker (MDA)
timeFrame: 4 weeks
Other outcomes:
Locations:
Study officials:
affiliation: Cairo U
name: Mona Taha Mohammed Ahammed, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06473376: Comparison Between Hegab Splint, Arthrocentesis, and Arthroscopy in Treatment of TMJ Closed Lock
Official title: Comparison Between of Hegab Splint, Arthrocentesis, and Arthroscopy in Treatment of TMJ Closed Lock
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: TMJ Disorder
TMJ Disc Disorder
Lead sponsor: Al-Azhar University
Sponsor class: OTHER
First posted: 2024-06-25
Enrollment: 45
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: The patients were randomly assigned to one of the following three groups: Group I (Control): patients treated by Hegab splint. Group II: patients treated by arthrocentesis with injection of HA/PRP mix plus Hegab splint. Group III: arthroscopy with injection of HA/PRP mix plus Hegab splint. The primary outcome variable was the change in pain using a visual analog scale, and improvement of maximum voluntary mouth opening. The secondary outcome variable was the change in joint sound. The third category of variables (age and sex) was evaluated in relation to the outcomes
Primary purpose: TREATMENT

Brief summary: This prospective, randomized control study aimed to compare the Clinical Outcome of Hegab splint, Arthrocentesis, and Arthroscopy in treatment of TMJ closed lock. The study sample was derived from the population of patients who presented for evaluation and treatment of TMJ disorders.

Detailed description: This prospective, randomized control study aimed to compare the Clinical Outcome of Hegab splint, Arthrocentesis, and Arthroscopy in treatment of TMJ closed lock. The study sample was derived from the population of patients who presented for evaluation and treatment of TMJ disorders. The patients were randomly assigned to one of the following three groups: Group I (Control): patients treated by Hegab splint. Group II: patients treated by arthrocentesis with injection of HA/PRP mix plus Hegab splint. Group III: arthroscopy with injection of HA/PRP mix plus Hegab splint. The primary outcome variable was the change in pain using a visual analog scale, and improvement of maximum voluntary mouth opening. The secondary outcome variable was the change in joint sound. The third category of variables (age and sex) was evaluated in relation to the outcomes.

Eligibility criteria: Inclusion Criteria:

* Patients with TMJ closed lock confirmed

Exclusion Criteria:

* rheumatoid arthritis psoriatic arthritis juvenile arthritis those receiving anticoagulant therapy

Primary outcomes:
measure: change in pain using a visual analog scale,
timeFrame: one year
measure: improvement of maximum voluntary mouth opening
timeFrame: one year
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Al-Azhar UNIVERSITY
city: Cairo
country: Egypt
facility: Prof.Hegab
Study officials:
References:
Clinical trial NCT01775176: Effect of Weight & Insulin Sensitivity on Reproductive Function in PCOS: Studies in Skeletal Muscle & Adipose
Official title: Effect of Weight and Insulin Sensitivity on Reproductive Function in Polycystic Ovary Syndrome: Studies in Skeletal Muscle and Adipose Tissue 'PULSE Ancillary Study'
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Polycystic Ovary Syndrome
Keywords: PCOS, Weight, Insulin Sensitivity, Reproductive Function
Lead sponsor: Pennington Biomedical Research Center
Sponsor class: OTHER
First posted: 2013-01-24
Enrollment: 17
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Overweight women with polycystic ovary syndrome.

20 - 40 years, inclusive Body mass index ≥ 25kg/m2 History of irregular menstrual cycles (fewer than 8 regular cycles in the past year) Clinical and/or biochemical androgen excess (Free androgen index\>3.85 and/or hirsuitism rating ≥8) Anovulatory menstrual cycles (determined during screening)

Brief summary: The overall objective of this ancillary study is to obtain skeletal muscle and subcutaneous adipose tissue biopsies from women with polycystic ovary syndrome enrolled in the PULSE Study (NCT01482286).

Detailed description: Muscle and adipose tissues will be appropriately collected and banked for future studies such as to measure expression of candidate genes involved with carbohydrate and fat oxidation and mitochondrial function by RT-PCR, protein content by western blot, enzyme activity by enzymatic assays and to perform functional studies under varying conditions (for example before and after treatment with insulin, testosterone, serum) to quantify insulin signaling and carbohydrate and fat oxidation in primary human cultures.

Eligibility criteria: Inclusion Criteria:

* Enrolled in PULSE NCT01482286

Exclusion Criteria:

* Withdraw from PULSE NCT01482286

Primary outcomes:
measure: Bio specimens for future research
timeFrame: 10 years
Secondary outcomes:
Other outcomes:
Locations:
city: Baton Rouge
country: United States
facility: Pennington Biomedical Research Center
state: Louisiana
Study officials:
affiliation: Pennington Biomedical Research Center
name: Leanne M Redman, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01574976: Effect of Feedback and Practice on Probabilistic Decision Making in Attention Deficit and Hyperactivity Disorder
Official title: Effect of Feedback and Practice on Probabilistic Decision Making in Attention Deficit and Hyperactivity Disorder
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: ADHD
Keywords: ADHD
probabilistic
choice
feedback
practice
Lead sponsor: Shaare Zedek Medical Center
Sponsor class: OTHER
First posted: 2012-04-10
Enrollment: 80
Sex: ALL
Minimum age (years): 13
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: The purpose of this study is to determine how feedback and practice affect decision making in adolescents with attention deficit and hyperactivity disorder.

Participants will have to choose between low and certain outcome and a higher but uncertain outcome, with or without serial feedback after each trial. Participants will perform the task twice to examine practice effects.


Eligibility criteria: Inclusion Criteria:

* ADHD

Exclusion Criteria:

* Current major depression,
* Psychosis,
* Autism,
* Tourette syndrome

Primary outcomes:
measure: probabilistic choice
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Jerusalem
country: Israel
facility: Shaare Zedek Medical Center
Study officials:
affiliation: Shaare Zedek Medical Center
name: Yehuda Pollak, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01082276: Rifampin Drug-Drug Interaction Study With Lurasidone HCl
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Male, Healthy Normal Subjects
Keywords: Rifampin DDI with Lurasidone HCl
Lead sponsor: Sumitomo Pharma America, Inc.
Sponsor class: INDUSTRY
First posted: 2010-03-08
Enrollment: 20
Sex: MALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP

Brief summary: The effect of rifampin on the pharmacokinetics of lurasidone

Detailed description: by performing an open-label, 2-period, sequential study in healthy subjects. All subjects (N=20) will be assigned to the same treatment sequence, 40 mg po dosing.

Eligibility criteria: Inclusion Criteria:

1. Female subjects must be of nonchildbearing potential (surgically sterile \[hysterectomy or bilateral tubal ligation\] or post-menopausal ≥ 1 year) with follicle stimulating hormone \[FSH\] \> 40 U/L).
2. Subjects with partners of child-bearing potential must agree to use barrier contraception during the study and for 90 days after discharge. Volunteers must agree to not donate sperm during the study and for 90 days after discharge.

Exclusion Criteria:

1. Any disorder that would interfere with the absorption, distribution, metabolism, or excretion of drugs.
2. Use of concomitant medications that prolong the QT/QTc interval from 14 days prior to day - 2 to discharge.
3. Use of any inhibitor or inducer of CYP3A4 taken within 30 days prior to study Day -2
4. Use of (an) investigational drug(s) within the 30 days or 5 half-lives (whichever was longer) prior to Screening.
5. Previous exposure to lurasidone (SM-13496).

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Baltimore
country: United States
facility: PAREXEL Clinical Pharmacology Research Unit
state: Maryland
Study officials:
affiliation: PAREXEL Clinical Pharmacology Research Unit at Baltimore, MD
name: Ronald Goldwater, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02618876: Effect of Caudal Nalbuphine on Postoperative Analgesia in Children
Official title: Nalbuphine as an Adjuvant to Caudal Bupivacaine for Postoperative Analgesia in Children Undergoing Hypospadias Repair
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Postoperative Pain
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2015-12-02
Enrollment: 60
Sex: MALE
Minimum age (years): 2
Maximum age (years): 10
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Nalbuphine as an adjuvant to bupivacaine caudal anesthesia for postoperative analgesia in children undergoing Hypospadias repair.

2 groups, 30 patients each


Eligibility criteria: Inclusion Criteria:

* Children undergoing elective Hypospadias repair
* with American Society of Anesthesiologists (ASA) physical status I
* age 2-10 years

Exclusion Criteria:

* Coagulation disorder
* allergy to study medications
* major malformations of the lower spine or meninges or any cutaneous or subcutaneous lesion at the site of injection.

Primary outcomes:
measure: Postoperative pain intensity Measured by Face, Legs, Activity, Cry & consolability (FLACC) pain scale
timeFrame: During 24 h in the postoperative period
Secondary outcomes:
measure: Cortisol level
timeFrame: 6 hours
Other outcomes:
Locations:
city: Assiut
country: Egypt
facility: Assiut University Hospital
Study officials:
References:
Clinical trial NCT02210676: Residual Extensor Lag Approximately 1 Month After Splint or Cast Immobilization of a Mallet Finger
Official title: Residual Extensor Lag Approximately 1 Month After Splint or Cast Immobilization of a Mallet Finger
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Patients Present With Mallet Finger
Lead sponsor: Massachusetts General Hospital
Sponsor class: OTHER
First posted: 2014-08-07
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: Aim:

The purpose of the study is to learn more about how a person recovers after treatment for mallet finger injury. The investigators want to identify the best outcome after mallet finger injury and how to improve treatment strategies.

Primary null hypothesis:

There are no statistically significant factors associated with extensor lag between 4 weeks and 4 months after immobilization is discontinued for a mallet finger among demographic, injury, and treatment factors.

Secondary null hypothesis:

There are no statistically significant factors associated with PROMIS upper extremity function between 4 weeks and 4 months after completion of immobilization for a mallet finger among demographic, psychological, injury, and treatment factors.


Eligibility criteria: Inclusion Criteria:

* 18 years of age and older
* English fluency and literacy
* Mallet finger fracture or non-fracture
* Mallet finger subluxation or non-subluxation

Exclusion Criteria:

* Pregnant Women

Primary outcomes:
measure: Mallet Finger Extensor Lag
timeFrame: Baseline
measure: Mallet Finger Extensor Lag
timeFrame: 4 weeks to 4 months after diagnosis
Secondary outcomes:
measure: Patient Reported Outcomes Measure Information System (PROMIS) Upper Extremity
timeFrame: 4 weeks to 4 months after diagnosis
measure: Likert Pain Scale
timeFrame: 4 weeks to 4 months after diagnosis
measure: Demographics Questionnaire
timeFrame: 4 weeks to 4 months after diagnosis
Other outcomes:
Locations:
city: Boston
country: United States
facility: Massachusetts General Hospital
state: Massachusetts
Study officials:
affiliation: Massachusetts General Hospital
name: David Ring, MD PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02787876: Pegteograstim in Children With Solid Tumors
Official title: Efficacy and Safety of Pegteograstim on Chemotherapy-induced Neutropenia in Children With Solid Tumors
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Chemotherapy Induced Neutropenia
Pediatric Solid Tumor
Lead sponsor: Samsung Medical Center
Sponsor class: OTHER
Collaborators: name: Green Cross Corporation
First posted: 2016-06-01
Enrollment: 34
Sex: ALL
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To evaluate the efficacy and safety of pegteograstim on chemotherapy-induced neutropenia in children with solid tumors

Detailed description: Children with solid tumor experience neutropenia after cytotoxic chemotherapy, and they usually receive granulocyte colony-stimulating factor (G-CSF) to stimulate neutrophil recovery. However it needs daily injection of G-CSF. Pegteograstim is a new formulation of PEGylated recombinant human G-CSF analogue pegfilgrastim. In this study, investigators aimed to evaluate the efficacy and safety of pegteograstim on chemotherapy-induced neutropenia in children with solid tumors.

Eligibility criteria: Inclusion Criteria:

* Patients with solid tumor who undergo chemotherapy with carboplatin, etoposide, doxorubicin, cyclophosphamide (CEDC) and ifosfamide, carboplatin, etoposide (ICE) regimen

Exclusion Criteria:

* Patients with organ dysfunction (creatinine \> 2mg/dL, ejection fraction \<40% or severe arrhythmia/conduction disorder, other severe organ dysfunction)
* Hypersensitivity to pegteograstim, protein originated from E-coli, pegfilgrastim, filgrastim or latex.
* Patients with bleeding tendency to whom subcutaneous injection should be avoided.
* Active infection or infectious fever during the screening period.
* Genetic problem to fructose tolerance.
* Patients who participated in other clinical trial within 4 weeks before enrollment.
* Pregnant and nursing women

Primary outcomes:
measure: Rate of adverse events
timeFrame: Up to 3 weeks after the injection of pegteograsim
measure: Duration of neutropenia (absolute neutrophil count (ANC) < 500/uL)
timeFrame: Up to 6 weeks
Secondary outcomes:
measure: Duration of severe neutropenia (ANC < 100/uL)
timeFrame: Up to 6 weeks
measure: Lowest value of ANC
timeFrame: Up to 6 weeks
measure: Days with neutropenic fever
timeFrame: Up to 6 weeks
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Samsung Medical Center
Study officials:
References:
citation: Cho HW, Lee JW, Ju HY, Hyun JK, Yoo KH, Koo HH, Kim K, Sung KW. Safety and Efficacy of Pegteograstim on Chemotherapy-induced Neutropenia in Children and Adolescents With Solid Tumors. J Pediatr Hematol Oncol. 2022 Mar 1;44(2):e362-e367. doi: 10.1097/MPH.0000000000002206.
Clinical trial NCT01539876: Tumour Necrosis Factor Release in Locally Advanced Breast Cancer Patients Receiving Neoadjuvant Docetaxel
Official title: Assessing Serial Tumour Necrosis Factor Release in Locally Advanced Breast Cancer Patients Receiving Neo-adjuvant Taxane Chemotherapy
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE1
Conditions: Breast Cancer
Keywords: locally advanced breast cancer patients
Lead sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Sponsor class: OTHER
First posted: 2012-02-28
Enrollment: 0
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: The purpose of this study is to assess the fine needle aspiration methodology in collecting sufficient tumour cells to measure tissue TNFa levels serially in human breast cancer sample receiving Taxane treatment

Detailed description: This pilot study will begin to test the clinical relevance of the TNFa pathway in docetaxel response in breast cancer patients receiving Taxane chemotherapy.

- Assess whether docetaxel can induce TNFa expression in breast cancer patients being treated with docetaxel

Eligibility criteria: Inclusion Criteria:

* Biopsy proven LABC, Locally advanced breast cancer. (operable or non-operable)
* Any T3/T4 or N2, N3 Clinical TNM stage breast cancer without metastases
* ECOG Performance Status of 0, 1 or 2.
* Patients should be able to comprehend the Letter of Information and be capable of giving informed consent.
* Female age 18 years old
* History and physical
* Negative serum pregnancy test for women of child bearing age

Exclusion Criteria:

* Inflammatory cancer (as defined by clinical evidence of dermal-lymphatic tumour involvement.)
* Ineligible for chemotherapy
* Patients with metastatic disease.
* Patients who have received prior chemotherapy or radiotherapy for this or any other malignancy.
* Previous breast cancer diagnosis
* Pregnant or lactating females are ineligible.
* Female patients of reproductive potential who decline to employ an adequate contraceptive method are ineligible.
* Participation in any concomitant trials.

Primary outcomes:
measure: measure tissue TNFa levels
timeFrame: 18 months
Secondary outcomes:
Other outcomes:
Locations:
city: London
country: Canada
facility: London Regional Cancer Program of the Lawson Health Research Institute
state: Ontario
Study officials:
affiliation: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
name: Muriel Brackstone, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01981876: Study of Esophageal Squamous Dysplasia Prevalence at Tenwek Hospital
Official title: Study of Esophageal Squamous Dysplasia Prevalence at Tenwek Hospital
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Esophageal Dysplasia
Keywords: Dysplasia
Esophageal Squamous Cell Carcinoma
Lead sponsor: Tenwek Hospital
Sponsor class: OTHER
Collaborators: name: Kenyatta National Hospital
name: Mayo Clinic
name: AORTIC
First posted: 2013-11-13
Enrollment: 305
Sex: ALL
Minimum age (years): 20
Maximum age (years): 79
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult Asymptomatic subjects residing within a 50 kilometer radius of Tenwek Hospital

Brief summary: Esophageal squamous cell cancer (ESCC) is common in the developing world, and is the leading cancer diagnosis at Tenwek Hospital in southwestern Kenya. The investigators long-term goal is to understand the pathogenesis and risk factors for ESCC in Kenya, and to establish effective screening and prevention programs. The investigators hypothesize that asymptomatic esophageal squamous dysplasia (ESD) is common in their region, and the current protocol is designed to determine the prevalence of ESD in residents of southwestern Kenya.

Detailed description: The prevalence of esophageal squamous dysplasia will be determined after evaluating pathology reports from unstained lesions and normal biopsies after staining with Lugol's iodine.

Eligibility criteria: Inclusion Criteria:

* Age ≥ 20 years
* No dysphagia (subjects will be asked "do you have trouble swallowing food or water? Do they get stuck inside after you swallow?" in their primary language

Exclusion Criteria:

* Cardiac, respiratory, or metabolic disease that would increase the risk of endoscopy: history of myocardial infarction, arrhythmias, chronic obstructive pulmonary disease, diabetes, allergy to lidocaine.
* Unable or unwilling to provide informed consent.

Primary outcomes:
measure: Percentage rate of subjects with Esophageal Squamous dysplasia calculated as Prevalence
timeFrame: 2 years
Secondary outcomes:
measure: percentage of subjects with severe esophageal squamous dysplasia calculated as a prevalence
timeFrame: 2 years
measure: percentage of subjects with moderate esophageal squamous dysplasia calculated as a prevalence
timeFrame: 2 years
measure: percentage of subjects with mild esophageal squamous dysplasia calculated as a prevalence
timeFrame: 2 years
Other outcomes:
measure: Distribution of dysplasia rate by age
timeFrame: 2 years
measure: Distribution of unstained lesions on the esophagus by anatomic location
timeFrame: 2 years
measure: Distribution of dysplasia rate by gender
timeFrame: 2 years
Locations:
city: Bomet
country: Kenya
facility: Tenwek Hospital
state: Riftvalley
Study officials:
affiliation: Tenwek Hospital
name: Michael M Mwachiro, MBChB
role: PRINCIPAL_INVESTIGATOR
affiliation: Tenwek Hospital
name: Russ E White, MD
role: STUDY_CHAIR
References: